Генерализованный линейный порокератоз у ребенка: клинический случай

Обоснование. Линейный порокератоз — редкий тип порокератоза, генетически детерминированное нарушение мевалонатного пути в кератиноцитах. Характеризуется высоким риском развития злокачественных новообразований (плоскоклеточный рак, базальноклеточный рак, болезнь Боуэна, меланома). Патогенетическое лечение не разработано. Описание клинического случая. Пациент К., возраст 8 лет, высыпания с первых дней жизни. С возрастом высыпания распространились по всему телу. На фоне приема ацитретина в дозировке 10 мг/сут спустя 3 мес отмечен положительный эффект в виде регресса части высыпаний. Заключение. Показан положительный эффект лечения линейного порокератоза ацитретином. Однако по-прежнему актуальным остается определение стандартных схем лечения порокератоза.

1. Saleva-Stateva M, Hess M, Technau-Hafsi K, et al. Molecular characterization and natural history of linear porokeratosis: A case series. J Am Acad Dermatol. 2021;85(6):1603–1606. doi: https://doi.org/10.1016/j.jaad.2020.11.061

2. Yang J, Du YQ, Fang XY, et al. Linear porokeratosis of the foot with dermoscopic manifestations: A case report. World J Clin Cases. 2022;10(31):11585–11589. doi: https://doi.org/10.12998/wjcc.v10.i31.11585

3. Vargas-Mora P, Morgado-Carrasco D, Fustà-Novell X. Porokeratosis: A Review of Its Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment. Actas Dermosifiliogr (Engl Ed). 2020;111(7):545–560. doi: https://doi.org/10.1016/j.ad.2020.03.005

4. Pietkiewicz P, Korecka K, Salwowska N, et al. Porokeratoses — A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants. Metabolites. 2023;13(12):1176. doi: https://doi.org/10.3390/metabo13121176

5. Yadav P, Sanke S, Mendiratta V, Chander R. Generalized Linear Porokeratosis in a Bilateral Distribution: An Unusual Presentation. Skinmed. 2022;20(3):220–223.

6. Atzmony L, Khan HM, Lim YH, et al. Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis. JAMA Dermatol. 2019;155(5):548–555. doi: https://doi.org/10.1001/jamadermatol.2019.0016

7. Ansari F, Mudugal R, Singh S, et al. Hystrix-like linear porokeratosis: a clinicopathological challenge. Int J Dermatol. 2022;61(2):e76–e79. doi: https://doi.org/10.1111/ijd.15711

8. Zhang Z, Li C, Wu F, et al. Genomic variations of the mevalonate pathway in porokeratosis. Elife. 2015;4:e06322. doi: https://doi.org/10.7554/eLife.06322

9. Touitou I. Twists and turns of the genetic story of mevalonate kinase-associated diseases: A review. Genes Dis. 2021;9(4): 1000–1007. doi: https://doi.org/10.1016/j.gendis.2021.05.002

10. Kostopoulos-Kanitakis KA, Kanitakis J. Porokeratoses: an update on pathogenesis and treatment. Int J Dermatol. 2025;64(1):62–71. doi: https://doi.org/10.1111/ijd.17411

11. Tappel AC, Tiwari N, Zlotoff B. Linear porokeratosis associated with Bardet-Biedl syndrome: A case report. Pediatr Dermatol. 2019;36(3):346–348. doi: https://doi.org/10.1111/pde.13776

12. Anderska A, Kaczmarska-Such A, Mazur E, Reich A. Porokeratoses-A Rare Group of Dermatoses. Medicina (Kaunas). 2024;60(11):1876. doi: https://doi.org/10.3390/medicina60111876

13. Lu JD, Mufti A, Sachdeva M, et al. Drugs associated with development of porokeratosis: A systematic review. Dermatol Ther. 2021;34(1):e14560. doi: https://doi.org/10.1111/dth.14560

14. Novice T, Nakamura M, Helfrich Y. The Malignancy Potential of Porokeratosis: A Single-Center Retrospective Study. Cureus. 2021;13(2):e13083. doi: https://doi.org/10.7759/cureus.13083

15. Williams GM, Dreyer MA, Fillman EP. Porokeratosis. 2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.

16. Inci R, Zagoras T, Kantere D, et al. Porokeratosis is one of the most common genodermatoses and is associated with an increased risk of keratinocyte cancer and melanoma. J Eur Acad Dermatol Venereol. 2023;37(2):420–427. doi: https://doi.org/10.1111/jdv.18587

17. Shirahatti T, Bangaru H, Sathish S. A Clinico-Epidemiological Study on Porokeratosis. Indian J Dermatol. 2024;69(4):365. doi: https://doi.org/10.4103/ijd.ijd_131_24

18. Zaar O, Polesie S, Navarrete-Dechent C, et al. Dermoscopy of porokeratosis: results from a multicentre study of the International Dermoscopy Society. J Eur Acad Dermatol Venereol. 2021;35(10):2091–2096. doi: https://doi.org/10.1111/jdv.17439

19. Noble CA, Bhate C, Duong BT, et al. Clinical-pathologic correlation: The impact of grossing at the bedside. Semin Diagn Pathol. 2025;42(2):150836. doi: https://doi.org/10.1053/j.semdp.2024.01.007

20. Atzmony L, Ugwu N, Hamilton C, et al. Inflammatory linear verrucous epidermal nevus (ILVEN) encompasses a spectrum of inflammatory mosaic disorders. Pediatr Dermatol. 2022;39(6): 903–907. doi: https://doi.org/10.1111/pde.15094

21. Shiiya C, Aoki S, Nakabayashi K, et al. Linear and disseminated porokeratosis in one family showing identical and independent second hits in MVD among skin lesions, respectively: a proofof-concept study. Br J Dermatol. 2021;184(6):1209–1212. doi: https://doi.org/10.1111/bjd.19824

22. Zhang W, Nie X, Shi L, et al. A Novel PMVK Variant Associated with Familial Porokeratosis. Hum Hered. 2023;88(1):50–57. doi: https://doi.org/10.1159/000531120

23. Kubo A, Sasaki T, Suzuki H, et al. Clonal Expansion of SecondHit Cells with Somatic Recombinations or C>T Transitions Form Porokeratosis in MVD or MVK Mutant Heterozygotes. J Invest Dermatol. 2019;139(12):2458–2466.e9. doi: https://doi.org/10.1016/j.jid.2019.05.020

24. Weidner T, Illing T, Miguel D, Elsner P. Treatment of Porokeratosis: A Systematic Review. Am J Clin Dermatol. 2017;18(4):435–449. doi: https://doi.org/10.1007/s40257-017-0271-3

25. Мурашкин Н.Н., Амбарчян Э.Т., Епишев Р.В., Материкин А.И., Опрятин Л.А., Иванов Р.А., Куколева Д.С. Фотодерматозы в детском возрасте. Вопросы современной педиатрии. 2021;20(5):360–369. doi: 10.15690/vsp.v20i5.2308.

26. Abbott-Frey AM, Coromilas AJ, Niedt GW, Lewin JM. Recurrent Squamous Cell Carcinoma Arising Within a Linear Porokeratosis. J Drugs Dermatol. 2020;19(2):205–206. doi: https://doi.org/10.36849/JDD.2020.4640.